Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: A 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study

Journal of Clinical Pharmacology

Volumn 52, Issue 12, 2012, Pages 1879-1890

  Boulton, Craig ^a   Meiser, Karin ^b   David, Olivier J ^b   Schmouder, Robert ^c  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

antibody response; Fingolimod; healthy volunteers; multiple sclerosis; sphingosine 1 phosphate receptor modulator

Indexed keywords

FINGOLIMOD; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ABDOMINAL PAIN; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; BODY TEMPERATURE DISORDER; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEELING HOT; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LYMPHOCYTE COUNT; MALE; MOUTH ULCER; MYALGIA; NAUSEA; NORMAL HUMAN; NOTE; OROPHARYNX PAIN; PHARMACODYNAMICS; PROCEDURAL PAIN; PROCEDURAL SITE REACTION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; THORAX PAIN;

ADMINISTRATION, ORAL; ADULT; ANTIGENS; ANTIGENS, FUNGAL; CANDIDA ALBICANS; DOUBLE-BLIND METHOD; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; MALE; PNEUMOCOCCAL VACCINES; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES; TETANUS TOXOID; YOUNG ADULT;

EID: 84868613636     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011427908     Document Type: Note

References (23)

1. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010 ; 33 (2). 91-101
2. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009 ; 158 (5). 1173-1182
3. U.S. Food and Drug Administration. FDA approves first oral drug to reduce MS relapses. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm226755. Updated September28, 2010. Accessed April 29, 2011.
4. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362 (5). 402-415
5. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362 (5). 387-401
6. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004 ; 44 (5). 532-537
7. Hofmann M, Brinkmann V, Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol. 2006 ; 6 (13-14). 1902-1910
8. Schmouder R, Aradhye S, O'Connor P, Kappos L. Pharmacodynamic effects of oral fingolimod [abstract]. Mult Sclerosis. 2006 ; 12: S101
9. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 ; 71 (16). 1261-1267
10. Novartis Pharmaceuticals. GILENYA™ prescribing information. http://www.gilenya.com/index.jsp. Accessed January 24, 2011.
11. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004 ; 22: 745-763
12. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity. 2008 ; 28 (1). 122-133
13. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 2000 ; 164 (11). 5761-5770
14. Brinkmann V, Chen S, Feng L, Pinschewer D, Nikolova Z, Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc. 2001 ; 33 (1-2). 530-531
15. Francis G, Kappos L, O'Connor P, et al. Lymphocytes and fingolimod-temporal pattern and relationship with infections. Poster presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ; Gothenburg, Sweden ;..
16. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2003 (4). CD000422
17. Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep MMWR Morb Mortal Wkly Rep. 1997 ; 46 (37). 880
18. Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005 ; 3 (4). 214-220
19. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 2007 ; 9 (2). R38
20. Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine. 2005 ; 23 (43). 5113-5119
21. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004 ; 57 (5). 586-591
22. Delves PJ, Roitt IM. The immune system: first of two parts. N Engl J Med. 2000 ; 343 (1). 37-49
23. Delves PJ, Roitt IM. The immune system: second of two parts. N Engl J Med. 2000 ; 343 (2). 108-117